| SGBI Stock | | | USD 0 0.00 0.00% |
CEO
Mr. Thomas Striepe is Chief Executive Officer, Director of Sangui Biotech International Inc. He is Vice President Accounting and Controlling at Treukonzept Finance GmbH, Hamburg, Germany, a financial services company. Prior to joining Treukonezpt Finance GmbH in 2004, he held management positions in the accounting departments of several German and international corporations. He holds an MBA of Hamburg University. since 2008.
| Age | 61 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Phone | 49 40 609 3120 |
| Web | https://www.sanguibiotech.com |
Sangui Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.6411) % which means that it has lost $0.6411 on every $100 spent on assets. This is way below average. Sangui Biotech's management efficiency ratios could be used to measure how well Sangui Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Sangui Biotech International currently holds 48.9
K in liabilities with Debt to Equity
(D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States. Sangui Biotech International [SGBI] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Sangui Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sangui Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.